OrbiMed invests $4M in enzyme-device glucose monitor; Masimo gets FDA nod for fingertip pulse oximeter;

@FierceMedDev: Cleveland Clinic developing catheter for delivery of chemotherapy directly into the brain. FierceDrugDelivery story | Follow @FierceMedDev

@VarunSaxena2: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. FierceDrugDelivery story | Follow @VarunSaxena2

**@EmilyWFierce:**Theranos authorized new shares that would value the co. at $10B, 3 days before the WSJ article came out. Story | Follow @EmilyWFierce

Startup Blockade Medical won a financing to back its catheter-based devices to treat cerebral aneurysm and ischemic stroke. Details were undisclosed. More

Masimo ($MASI) gained FDA clearance for fingertip pulse oximeter MightySat Rx. More

OrbiMed Advisors invested $4 million in SmartZyme to develop its enzyme-device combination for diabetic blood glucose monitoring. The Israeli startup is hoping to license its technology next. More

Biotech News

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Interesting that most of the$PFE/$AGN discussion is around the mechanics of a deal, rather than a backlash against another megamerger. | Follow @JohnCFierce

@DamianFierce: | Follow @DamianFierce

Frazier unveils a $262M pure-play biotech venture fund. Story

Biotech IPOs are staggering as the bulls begin to fade back. Report

Ultragenyx launches an RNA collaboration with upstart Arcturus. Article

Pharma News

@FiercePharma: Investors cheer Abaxis but trounce IDEXX on quarterly diagnostics performance. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: IOYMI: Napp Pharmaceuticals says it is offering England's NHS Remsima for as much as 60% less than Remicade. Article| Follow @EricPFierce

@CarlyHFierce: GSK chief: We don't need a breakup or a Pfizer deal. Just look at ViiV's sales surge. Article | Follow @CarlyHFierce

Sanofi's Q3 bombshell: Diabetes sales drop, and will keep dropping through 2018. More

Q3 beats on sales, earnings ready Amgen for biosimilar attack. Story

Shopping for a tax-friendly megamerger, Pfizer zeroes in on self-styled 'growth pharma' Allergan. Article

CRO News

Icon ekes out another quarter of growth despite currency woes. More

INC boosts its outlook after another big revenue quarter. Report

Parexel's profits slide as it slashes costs. Story

Novartis, Qualcomm back trial startup's $6.5M round. Item

PRA upgrades its Dutch R&D hub with eyes on bioanalytics. Article

Pharma Manufacturing News

Pfizer and GSK to work together on continuous manufacturing. Item

Novartis' Sandoz plants in India cited in warning letter. More

Saline producers face call for FTC probe into shortage, rising prices. Report

States want FDA to quit seizing their execution drugs. Story

Aurobindo moves forward with plans for new U.S. plant. Article

Pharma Asia News

Novartis to close one Indian manufacturing plant as FDA warning bites. Article

Lupin hopes for more U.S. approvals as earnings drop 35%. Item

Health insurance companies still being targeted by Chinese hackers. Story

Cough syrup abuse gets India's attention. More

BMS sees sharper hep C competition in Japan in Q3. Report